PD-Rx Pharmaceuticals
Market Cap
US$6.6m
Last Updated
2019/09/18 23:39 UTC
Data Sources
Company Financials
Executive Summary
PD-Rx Pharmaceuticals, Inc. engages in the repackaging and distribution of prepackaged pharmaceutical products for the healthcare industry.
Snowflake
Fundamentals
Adequate balance sheet with weak fundamentals.
Risks
- PD-Rx Pharmaceuticals's last earnings update was 1000 days ago.
- PD-Rx Pharmaceuticals is not covered by any analysts.
Share Price & News
How has PD-Rx Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-3.3%
OTCPK:PDRX
-1.2%
US Healthcare
-0.02%
US Market
1 Year Return
-40.8%
OTCPK:PDRX
-9.4%
US Healthcare
1.6%
US Market
PDRX underperformed the Healthcare industry which returned -8.4% over the past year.
PDRX underperformed the Market in United States of America which returned 1.9% over the past year.
Share holder returns
| PDRX | Industry | Market | |
|---|---|---|---|
| 7 Day | -3.3% | -1.2% | -0.02% |
| 30 Day | -3.8% | -2.2% | 2.7% |
| 90 Day | n/a | -1.5% | 1.4% |
| 1 Year | -12.7%-40.8% | -8.0%-9.4% | 3.8%1.6% |
| 3 Year | 23.3%-24.5% | 28.7%23.5% | 45.2%35.8% |
| 5 Year | 17.5%-28.0% | 62.7%53.0% | 61.8%44.1% |
Price Volatility Vs. Market
How volatile is PD-Rx Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall St
Financially Strong And High Value StocksValuation
Is PD-Rx Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?
In this section, we usually try to help investors determine whether PD-Rx Pharmaceuticals is trading at an attractive price based on the cash flow it is expected to produce in the future. But as PD-Rx Pharmaceuticals has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
Next Steps
- Examine PD-Rx Pharmaceuticals's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through PD-Rx Pharmaceuticals regulatory filings here.
- Explore potentially undervalued companies in the Healthcare industry.
Future Growth
How is PD-Rx Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 0 analysts?
10.9%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as PD-Rx Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Examine PD-Rx Pharmaceuticals's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access PD-Rx Pharmaceuticals's filings and announcements here.
- Explore growth companies in the Healthcare industry.
Past Performance
How has PD-Rx Pharmaceuticals performed over the past 5 years?
0.1%
Historical Healthcare annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Insufficient past earnings data to establish if PD-Rx Pharmaceuticals's year on year earnings growth rate was positive over the past 5 years.
Unable to compare PD-Rx Pharmaceuticals's 1-year growth to the 5-year average as past earnings data has not been reported.
Unable to compare PD-Rx Pharmaceuticals's 1-year growth to the US Healthcare industry average as past earnings data has not been reported.
Return on Equity
Unable to establish if PD-Rx Pharmaceuticals has efficiently used shareholders’ funds last year as no Return on Equity data is available.
Return on Assets
Unable to establish if PD-Rx Pharmaceuticals has efficiently used its assets last year compared to the US Healthcare industry average (Return on Assets) as past financial data has not been reported.
Return on Capital Employed
Unable to establish if PD-Rx Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to insufficient past data.
Next Steps
Financial Health
How is PD-Rx Pharmaceuticals's financial position?
In this section we usually analyse PD-Rx Pharmaceuticals's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. PD-Rx Pharmaceuticals has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.
Next Steps
- Take a look at our analysis of PDRX’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
- Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when PD-Rx Pharmaceuticals's financial data was last updated here.
- Explore more healthy companies in the Healthcare industry.
Dividend
What is PD-Rx Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate PD-Rx Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate PD-Rx Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as PD-Rx Pharmaceuticals has not reported any payouts.
Unable to verify if PD-Rx Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as PD-Rx Pharmaceuticals has not reported any payouts.
Future Payout to Shareholders
Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
Next Steps
Management
What is the CEO of PD-Rx Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?
US$59k
CEO Compensation
CEO
Robert Holsey (66yo)
0yrs
Tenure
US$58,519
Compensation
Dr. Robert D. Holsey D.O., R.Ph. has been a Director of Pd-rx Pharmaceuticals Inc. since 1986 and serves as President, Chief Executive Officer and Chairman of the Board and a practicing physician. Dr. Hols ...
Insider Trading
No 3 month open market individual insider trading information.
Management Team
Jack McCall (59yo)
COO, Executive VP of Marketing & Sales
- Tenure: 23yrs
Robert Holsey (66yo)
Chairman
- Tenure: 0yrs
- Compensation: US$58.52k
Bob Baker (70yo)
CFO & Director
- Tenure: 23.1yrs
David Dare (66yo)
Treasurer and Director
- Tenure: 0yrs
Robert Surovec (70yo)
Regulatory Affairs Compliance Officer
- Tenure: 0yrs
Board Members
Jack McCall (59yo)
COO, Executive VP of Marketing & Sales
- Tenure: 23yrs
Robert Holsey (66yo)
Chairman
- Tenure: 0yrs
- Compensation: US$58.52k
Bob Baker (70yo)
CFO & Director
- Tenure: 23.1yrs
David Dare (66yo)
Treasurer and Director
- Tenure: 0yrs
Company Information
PD-Rx Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: PD-Rx Pharmaceuticals, Inc.
- Ticker: PDRX
- Exchange: OTCPK
- Founded: 1986
- Industry: Health Care Distributors
- Sector: Healthcare
- Market Cap: US$6.603m
- Shares outstanding: 1.72m
- Website: https://www.pdrx.com
Location
- PD-Rx Pharmaceuticals, Inc.
- 727 North Ann Arbor
- Oklahoma City
- Oklahoma
- 73127
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| PDRX | OTCPK (Pink Sheets LLC) | Yes | Common Shares | US | USD | Jan 1992 |
Biography
PD-Rx Pharmaceuticals, Inc. engages in the repackaging and distribution of prepackaged pharmaceutical products for the healthcare industry. It offers branded and generic pharmaceuticals, unit dose products ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/18 23:39 |
| End of Day Share Price | 2019/09/12 00:00 |
| Earnings | 2016/06/30 |
| Annual Earnings | 2016/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.